文献速递眼底病与葡萄膜炎神经眼科

急性白血病患者白血病性视网膜病变与视神经病变的临床表现及眼科结局

Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

该回顾性研究纳入276例急性白血病患者,其中55例发生白血病性视网膜病变和视神经病变(LRON),分为1、2a、2b、3型;3型均见于急性淋巴细胞白血病(ALL),2b和3型初始最佳矫正视力(BCVA)更差且3型随访无视力恢复;LRON存在与否未显著影响生存。

要点

  • LRON分4型,3型均见于ALL,其他类型主要见于AML。
  • 2b和3型初始BCVA更差,3型随访期间无BCVA恢复。
  • AML伴LRON者更常接受造血干细胞移植,且DNMT3A、IDH1、TET2共突变与LRON高风险相关(OR=16.41)。

核心结论

  • 研究描述了LRON各亚型不同的临床、遗传特征和视力结局。
  • 研究强调对急性白血病患者及时进行眼科会诊和视觉症状患者教育的重要性。

研究设计与样本

  • 回顾性收集276例急性白血病患者的眼科测量、治疗过程、实验室数据和分子谱,其中55例有LRON。

主要发现

  • 3型LRON患者均为ALL,其他类型LRON主要见于AML患者。
  • 2b型和3型LRON患者初始BCVA更差,3型LRON患者在随访期间无BCVA恢复。
  • AML伴LRON患者更常接受造血干细胞移植(P < 0.001),其白血病原始细胞更常表达CD7(P = 0.004)和CD38(P = 0.048),并携带DNMT3A(P = 0.017)和IDH1(P = 0.041)突变。
  • DNMT3A、IDH1和TET2突变共存与LRON风险特别高相关(比值比=16.41)。
  • ALL伴3型LRON患者中枢神经系统受累率(P = 0.041)和白血病复发率(P = 0.007)更高。

临床怎么用

  • 作者强调对急性白血病患者及时进行眼科会诊和视觉症状患者教育的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the clinical manifestations and visual outcomes of leukemic retinopathy and optic neuropathy (LRON) in patients with acute leukemia. METHODS: We recruited 276 patients with acute leukemia, 55 of whom had LRON. The ophthalmic measurements, treatment courses, laboratory data, and molecular profiling were retrospectively collected. RESULTS: Patients with LRON were classified as type 1, type 2a, type 2b, and type 3. All patients with type 3 LRON had acute lymphoblastic leukemia (ALL), while the other types of LRON mainly occurred in patients with acute myeloid leukemia (AML). Patients with type 2b and type 3 LRON had worse initial best-corrected visual acuity (BCVA); none of the patients with type 3 LRON had recovery of BCVA during follow-up. The patients with AML with LRON were more likely to undergo hematopoietic stem cell transplantation (P < 0.001); their leukemic blasts more frequently expressed CD7 (P = 0.004) and CD38 (P = 0.048) and harbored DNMT3A (P = 0.017) and IDH1 (P = 0.041) mutations. Notably, the co-occurrence of DNMT3A, IDH1, and TET2 mutations was associated with a particularly high risk of LRON (odds ratio = 16.41). The patients with ALL with type 3 LRON had higher rates of central nervous system involvement (P = 0.041) and relapsed leukemia (P = 0.007). Nevertheless, the presence of LRON did not significantly affect survival in acute leukemia. CONCLUSIONS: We characterized distinct clinical, genetic features and visual outcomes across LRON subtypes. Our study highlights the importance of prompt ophthalmic consultation and patient education regarding visual symptoms in acute leukemia.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Chen CY, Jhang JP, Lai YJ, et al. Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia. Invest Ophthalmol Vis Sci. 2025. PMID: 40747974. doi:10.1167/iovs.66.11.2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。